Research programme: rheumatoid arthritis therapy - Aphoenix

Drug Profile

Research programme: rheumatoid arthritis therapy - Aphoenix

Alternative Names: AFX 001 series; AFX-200 series; Rheumatoid arthritis therapy research programme - Aphoenix

Latest Information Update: 07 Mar 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Aphoenix
  • Class Small molecules
  • Mechanism of Action Cytokine inhibitors; Osteoclast inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 28 Jun 2005 Aphoenix has completed preclinical trials in Rheumatoid arthritis in Japan
  • 28 Jun 2004 AFX 001 series is available for partnering (
  • 28 Jun 2004 Preclinical trials in Rheumatoid arthritis in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top